^
    Back
    Association details:
    Biomarker:HLA-A*02 + H3K27M
    Cancer:Glioma
    Drug:Histone H3.3-K27M Neoantigen Vaccine Therapy (Immunostimulant)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2023
    Title:

    H3.3-K27M neoantigen vaccine elicits anti-tumor T cell immunity against diffuse intrinsic pontine glioma: The phase I ENACTING trial.

    Published date:
    05/25/2023
    Excerpt:
    Patients aged ≥ 5 years old with newly diagnosed DIPG were consented and screened. HLA-A*02+/H3.3-K27M+ patients were enrolled...One-year OS rate was 66.7% (95% CI: 42~100%)….The H3.3-K27M neoantigen vaccine was well tolerated. Initial results from this ongoing study suggest that, compared with other current therapies against DIPG, H3.3-K27M peptide vaccination may provide superior patient survival outcomes.
    DOI:
    10.1200/JCO.2023.41.16_suppl.2052
    Trial ID:
    ENACTING